Andrew Weickhardt

Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer

Robert C. Doebele, Amanda Pilling, Dara L. Aisner et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1K citations

Urology, Oncology, Genitourinary Cancer +7

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Andrew Weickhardt, Benjamin Scheier, Joseph Burke et al. · Journal of Thoracic Oncology · 2012 · 663 citations · Full text

Local Ablative Therapy, Oncology, Novel Therapy +8

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Robert C. Doebele, Xian Lu, Christopher Sumey et al. · Cancer · 2012 · 278 citations · Full text

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7